<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28589" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Rifaximin</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Robertson</surname>
            <given-names>Kyle D.</given-names>
          </name>
          <aff>McLaren Greater Lansing</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Nagalli</surname>
            <given-names>Shivaraj</given-names>
          </name>
          <aff>Yuma Regional Medical Center</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Kyle Robertson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Shivaraj Nagalli declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>22</day>
          <month>5</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28589.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Rifaximin is an antibiotic used to treat irritable bowel syndrome with diarrhea, reduce the risk of overt hepatic encephalopathy recurrence in adults, and treat travelers&#x02019; diarrhea caused by noninvasive strains of Escherichia coli. Rifaximin has a broad spectrum of activity against both gram-negative and gram-positive anaerobic and aerobic bacteria. This antibiotic is used primarily in diseases since it is specific to the gastrointestinal tract due to its nonabsorbable profile. This activity will review the indications, mechanism of action, administration, safety profile, and contraindications for rifaximin. In addition, this activity will highlight the mechanism of action, adverse event profile, and other key factors (e.g., off-label uses, dosing, pharmacodynamics, pharmacokinetics, monitoring, and relevant interactions) pertinent to the interprofessional team members.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Identify the mechanism of action of rifaximin.</p></list-item><list-item><p>Describe the adverse drug reactions of rifaximin therapy.</p></list-item><list-item><p>Review the indications for using rifaximin therapy on a patient.</p></list-item><list-item><p>Summarize interprofessional team strategies for improving care coordination and communication to advance rifaximin and improve outcomes.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28589&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28589">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-28589.s2" sec-type="Indications">
        <title>Indications</title>
        <p>Rifaximin is a nonabsorbable oral antibiotic. Rifaximin has a broad spectrum of activity against both gram-negative and gram-positive anaerobic and aerobic bacteria. This antibiotic is used primarily for gastrointestinal and liver diseases since it is specific to the gastroenterology tract due to its nonabsorbable profile. Rifaximin was first approved in the United States in 2004 but has been in use since 1987, when it first received approval in Italy.</p>
        <p>
<bold>In the United States, rifaximin is FDA-approved for the following indications.</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.<xref ref-type="bibr" rid="article-28589.r1">[1]</xref></p>
          </list-item>
          <list-item>
            <p>Reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults.<xref ref-type="bibr" rid="article-28589.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Treatment of travelers&#x02019; diarrhea (TD) caused by noninvasive strains of&#x000a0;<italic toggle="yes">Escherichia coli&#x000a0;</italic>in adults and pediatric patients 12 years of age and older.<xref ref-type="bibr" rid="article-28589.r3">[3]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Rifaximin is used for following non-FDA-approved(off-label) indications.</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Small intestinal bacterial overgrowth (SIBO)<xref ref-type="bibr" rid="article-28589.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Diverticulitis<xref ref-type="bibr" rid="article-28589.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Inflammatory bowel disease,&#x000a0;Pouchitis<xref ref-type="bibr" rid="article-28589.r6">[6]</xref></p>
          </list-item>
          <list-item>
            <p>Spontaneous bacterial peritonitis<xref ref-type="bibr" rid="article-28589.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p><italic toggle="yes">Clostridium difficile</italic>&#x000a0;infection (CDI)<xref ref-type="bibr" rid="article-28589.r8">[8]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28589.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Rifaximin is a synthetic antimicrobial derived from the parent compound, rifamycin. It has broad-spectrum bactericidal&#x000a0;activity against both gram-positive and gram-negative aerobic and anaerobic bacteria.<xref ref-type="bibr" rid="article-28589.r4">[4]</xref> Rifaximin has also&#x000a0;demonstrated an effect on enteric protozoa activity in HIV patients with <italic toggle="yes">Cryptosporidium parvum</italic> and <italic toggle="yes">Blastocystitis hominis</italic> intestinal infections. The medication acts on and inhibits the bacteria's ability to synthesize proteins. The drug accomplishes this by irreversibly binding to the bacterial DNA-dependent RNA polymerase called rpoB.<xref ref-type="bibr" rid="article-28589.r9">[9]</xref></p>
        <p>Because rifaximin is non-absorbable, it reaches high concentrations within the gastrointestinal lumen, allowing it to work effectively on various gastrointestinal diseases without systemic effects.<xref ref-type="bibr" rid="article-28589.r10">[10]</xref>&#x000a0;There is a very low incidence of bacterial mutation and drug resistance to rifaximin in extra-intestinal bacteria. However, long-term use of rifaximin can result in resistant bacterial mutants in the enteric system.<xref ref-type="bibr" rid="article-28589.r11">[11]</xref></p>
        <p>
<bold>Pharmacokinetics</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Absorption:</bold> According to the manufacturer's&#x000a0;information, the average time to reach peak rifaximin plasma concentrations in healthy subjects was about an hour. The mean Cmax ranged from 2.4 to 4 ng/mL after a single and multiple doses of rifaximin.&#x000a0;Mean rifaximin exposure (AUC) in patients with hepatic encephalopathy was approximately 12-fold higher. A high-fat meal consumed 30 minutes preceding rifaximin dosing in healthy subjects delayed the time to peak plasma concentration (Tmax) from 0.75 to 1.5 hours, increased the systemic exposure (AUC) by 2-fold but did not significantly impact Cmax.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Distribution:</bold> The mean protein binding&#x000a0;is 67.5% in healthy subjects and 62% in patients with hepatic impairment.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Metabolism:</bold>&#x000a0;Rifaximin&#x000a0;is metabolized mainly by CYP3A4. In addition, Rifaximin accounted for 18% of the radioactivity in plasma, suggesting that the absorbed rifaximin undergoes extensive metabolism.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Excretion:</bold>&#x000a0;The half-life of rifaximin in healthy subjects at steady-state plasma concentration was 5.6 hours and was 6 hours in IBS-D patients. In a mass balance study, when 14C-rifaximin was administered orally to healthy volunteers, of the 96.94% total recovery, 96.62% of the administered radioactivity was recovered in feces largely as the unchanged drug, 0.32% was recovered in the urine primarily as metabolites with 0.03% as the unchanged drug.&#x000a0;Biliary excretion of rifaximin was indicated by a further study in which rifaximin was present in the bile in patients with intact gastrointestinal mucosa after cholecystectomy.</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28589.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Rifaximin is administered orally and is typically available in 200 mg and 550 mg tablets. Since it is poorly absorbed in the gastrointestinal system, there are very low systemic blood levels. Most of the medication passes through the gastrointestinal tract and is excreted in the feces. The dose regimens&#x000a0;vary depending on the disease process the patient is receiving treatment.</p>
        <list list-type="bullet">
          <list-item>
            <p>For Irritable Bowel Syndrome with Diarrhea(IBS-D), the suggested dose of rifaximin is 400 mg three times or 550 mg twice daily for two weeks. IBS-D may require intermittent rifaximin treatment. Typically, 200 mg three times daily is given for three days in traveler's diarrhea. The recommended&#x000a0;dosage for preventing traveler's diarrhea is rifaximin 200 mg twice daily or 600 mg daily.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Hepatic encephalopathy requires a dose of 550 mg twice or three times daily and is usually continued&#x000a0;for an extended period&#x000a0;to prevent&#x000a0;its recurrence. Rifaximin is generally used in combination with lactulose to treat hepatic encephalopathy. For small intestinal bacterial overgrowth, the typical dose of rifaximin is 400 mg three times daily for two weeks. For patients with hepatic encephalopathy, recurrent treatment is warranted.&#x000a0;</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Studies show that rifaximin at a dose of 400 mg twice daily for seven days every month improves diverticular disease symptoms and prevents their recurrence. Pouchitis patients may need doses of 400 to even 800 mg twice daily for 12 weeks; they may need periodic retreatment. Recurrent <italic toggle="yes">Clostridium difficile</italic> treatment in retrospective studies and case series was 400 mg twice daily for two weeks. Spontaneous bacterial peritonitis prophylaxis should use rifaximin three times daily indefinitely.<xref ref-type="bibr" rid="article-28589.r11">[11]</xref></p>
          </list-item>
        </list>
        <p>
<bold>Use in Specific Patient Population</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p><bold>Hepatic Impairment:</bold>&#x000a0;According to manufacturer labeling, following administration of rifaximin in the patients with hepatic encephalopathy, the systemic exposure (i.e., AUC) of rifaximin is proportionately increased in patients with mild, moderate, and severe hepatic impairment. No dose modification is generally necessary for patients with mild or moderate hepatic impairment. However, caution should be exercised when rifaximin is administered to patients with severe hepatic impairment (Child-Pugh Class C).</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Renal Impairment:&#x000a0;</bold>According to manufacturer labeling, the pharmacokinetics of rifaximin in patients with impaired renal function have not been investigated. However, no dosage adjustment is typically necessary as the absorption of rifaximin is minimal.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Pregnancy Considerations:</bold> There is no data on the use of rifaximin in pregnant women to inform a drug-associated risk. However, teratogenic effects were observed in preclinical animal studies after the administration of rifaximin to pregnant rats and rabbits. In rabbits, maxillofacial, cardiac, ocular, and spine malformations were observed. In addition, ocular malformations were reported in both rats and rabbits. Consequently, pregnant patients should be advised of the potential harm to the fetus.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p><bold>Breastfeeding Considerations:&#x000a0;</bold>According to the manufacturer, the clinician should evaluate the developmental and health benefits of breastfeeding and the mother's clinical need for rifaximin, and any adverse effects on the breastfed infant from rifaximin. Rifaximin has poor oral absorption; therefore, it is not likely to reach the breastmilk or bloodstream of the infant and cause any adverse drug reactions in breastfed infants. Nevertheless, no published experience exists with rifaximin during breastfeeding; therefore, an alternate drug may be preferred, particularly while nursing a newborn or preterm infant.<xref ref-type="bibr" rid="article-28589.r12">[12]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28589.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>Rifaximin has an excellent safety profile due to its lack of systemic absorption. Clinical trials have shown that adverse effects of rifaximin are similar to or even lower frequency than placebo, trimethoprim-sulfamethoxazole, and ciprofloxacin. Clinical trials did not show any serious adverse events while using rifaximin. There were no deaths while using rifaximin in clinical trials. Rifaximin does not require dose adjustments for hepatic dysfunction.<xref ref-type="bibr" rid="article-28589.r9">[9]</xref></p>
        <p>There are published case reports of rifaximin interacting with warfarin, which resulted in reductions in INR levels.&#x000a0;<italic toggle="yes">In vivo</italic>&#x000a0;studies have previously shown that CYP3A4 can be induced by rifaximin, affecting the bioavailability of CYP3A4 substrates. Although these studies have demonstrated that rifaximin can affect CYP3A4 enzyme activity, this would likely never happen in a patient because of the minimal systemic absorption.<xref ref-type="bibr" rid="article-28589.r13">[13]</xref></p>
        <p>Patients treated with rifaximin may develop adverse drug reactions, including nausea, gastrointestinal upset, fatigue, peripheral edema, dizziness, and muscle spasms. In addition, long-term use has been associated with fungal or bacterial super-infections.&#x000a0;There is little evidence that rifaximin causes clinically apparent liver disease or serum enzyme elevations despite widespread use. Likelihood score: E (unlikely cause of clinically apparent liver injury).<xref ref-type="bibr" rid="article-28589.r13">[13]</xref></p>
      </sec>
      <sec id="article-28589.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>Due to&#x000a0;the excellent safety profile of rifaximin, there are very few contraindications.</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients with hypersensitivity to the rifaximin, rifamycins, or&#x000a0;excipients&#x000a0;should avoid this medication as hypersensitivity reactions like exfoliative dermatitis, angioneurotic edema, and anaphylaxis have been reported.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Concomitant administration of P-glycoprotein (P-gp) inhibitors such as cyclosporine with rifaximin can substantially augment the systemic exposure to rifaximin and can lead to toxicity.</p>
          </list-item>
        </list>
        <list list-type="bullet">
          <list-item>
            <p>Severe Hepatic Impairment: There is increased systemic exposure to rifaximin in patients with severe hepatic impairment. The clinical trials were conducted only on patients with MELD scores &#x0003c;25. Therefore, caution should be exercised when administering rifaximin in patients with severe hepatic impairment (Child-Pugh Class C).<xref ref-type="bibr" rid="article-28589.r14">[14]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28589.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Rifaximin demonstrates poor absorption into the systemic blood system, and only trace amounts appear in the blood and urine following administration. Prior studies have shown less than 0.4% of the medication detectable in the blood or urine and undetectable levels in bile and breast milk. For this reason, the monitoring of rifaximin is unnecessary.<xref ref-type="bibr" rid="article-28589.r9">[9]</xref></p>
        <p>However, the clinician should monitor disease progression (e.g., response to rifaximin treatment can be monitored by lactulose breath test in patients with&#x000a0;IBS-D).<xref ref-type="bibr" rid="article-28589.r15">[15]</xref></p>
      </sec>
      <sec id="article-28589.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Since rifaximin is poorly absorbed into the systemic blood system and passes through the digestive tract, there is no evidence to suggest there can be an accumulation of toxic levels in the body. There is no antidote to rifaximin. No specific information is available regarding the treatment of overdosage with rifaximin.</p>
        <p>However, as per the manufacturer's label, in clinical studies at doses higher than the recommended dose, adverse reactions were similar in subjects who received doses higher than the recommended dosage. However, like in any case of overdose, the clinician should discontinue rifaximin, institute supportive measures, and treat symptomatically.</p>
      </sec>
      <sec id="article-28589.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Although rifaximin has only been FDA-approved in the United States since 2004, new clinical trials and new off-label uses are continually under investigation. Therefore, it is essential to know FDA-approved and off-label uses. This medication is often a therapeutic choice for gastroenterologists, hospitalists, family medicine practitioners, and pharmacists. In addition, the fact that it has practically no contraindications, no need for monitoring, and no known toxicity makes it an ideal drug for patients with numerous gastrointestinal disorders.</p>
        <p>Resistance to rifaximin is caused predominantly by mutations in the rpoB gene. The mutation in the rpoB gene changes the binding site on DNA-dependent RNA polymerase and reduces rifaximin binding affinity.&#x000a0;Antimicrobial resistance (AMR) is a danger to global public health. It increases morbidity and mortality and leads to the development of multidrug-resistant pathogens. An antimicrobial stewardship program is a system-wide healthcare strategy designed to encourage, improve, monitor, and evaluate the rational use of antimicrobials to maintain their future efficacy against microorganisms.&#x000a0;Hence it is the responsibility of the entire healthcare team, including clinicians, infectious disease specialists, nurses, and pharmacists, to promote the rational use of antibiotics such as rifaximin.<xref ref-type="bibr" rid="article-28589.r16">[16]</xref></p>
        <p>It is important to consider that for prescribing rifaximin; insurance approval has to be obtained. Practitioners and nurses that are well versed and capable should be able to manage prior authorization of the medication.<xref ref-type="bibr" rid="article-28589.r17">[17]</xref>&#x000a0;It is always essential to evaluate whether rifaximin is the right management strategy and consider evidence-based strategies to optimize patient care.</p>
      </sec>
      <sec id="article-28589.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28589&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28589">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28589/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28589">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28589.s11">
        <title>References</title>
        <ref id="article-28589.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brenner</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Sayuk</surname>
                <given-names>GS</given-names>
              </name>
            </person-group>
            <article-title>Current US Food and Drug Administration-Approved Pharmacologic Therapies for the Treatment of Irritable Bowel Syndrome with Diarrhea.</article-title>
            <source>Adv Ther</source>
            <year>2020</year>
            <month>Jan</month>
            <volume>37</volume>
            <issue>1</issue>
            <fpage>83</fpage>
            <page-range>83-96</page-range>
            <pub-id pub-id-type="pmid">31707713</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Bass</surname>
                <given-names>NM</given-names>
              </name>
              <name>
                <surname>Mullen</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Sanyal</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Poordad</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Neff</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Leevy</surname>
                <given-names>CB</given-names>
              </name>
              <name>
                <surname>Sigal</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sheikh</surname>
                <given-names>MY</given-names>
              </name>
              <name>
                <surname>Beavers</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Frederick</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Teperman</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Hillebrand</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Merchant</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Shaw</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Bortey</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Forbes</surname>
                <given-names>WP</given-names>
              </name>
            </person-group>
            <article-title>Rifaximin treatment in hepatic encephalopathy.</article-title>
            <source>N Engl J Med</source>
            <year>2010</year>
            <month>Mar</month>
            <day>25</day>
            <volume>362</volume>
            <issue>12</issue>
            <fpage>1071</fpage>
            <page-range>1071-81</page-range>
            <pub-id pub-id-type="pmid">20335583</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cottreau</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Baker</surname>
                <given-names>SF</given-names>
              </name>
              <name>
                <surname>DuPont</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>Garey</surname>
                <given-names>KW</given-names>
              </name>
            </person-group>
            <article-title>Rifaximin: a nonsystemic rifamycin antibiotic for gastrointestinal infections.</article-title>
            <source>Expert Rev Anti Infect Ther</source>
            <year>2010</year>
            <month>Jul</month>
            <volume>8</volume>
            <issue>7</issue>
            <fpage>747</fpage>
            <page-range>747-60</page-range>
            <pub-id pub-id-type="pmid">20586560</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gatta</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Scarpignato</surname>
                <given-names>C</given-names>
              </name>
            </person-group>
            <article-title>Systematic review with meta-analysis: rifaximin is effective and safe for the treatment of small intestine bacterial overgrowth.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>45</volume>
            <issue>5</issue>
            <fpage>604</fpage>
            <page-range>604-616</page-range>
            <pub-id pub-id-type="pmid">28078798</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Brandimarte</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Bafutto</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Kruis</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Scarpignato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Mearin</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Barbara</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>&#x00160;timac</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Vrani&#x00107;</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cassieri</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Lecca</surname>
                <given-names>PG</given-names>
              </name>
              <name>
                <surname>D'Avino</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Malfertheiner</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Hot Topics in Medical Treatment of Diverticular Disease: Evidence Pro and Cons.</article-title>
            <source>J Gastrointestin Liver Dis</source>
            <year>2019</year>
            <month>Dec</month>
            <day>19</day>
            <volume>28</volume>
            <issue>suppl. 4</issue>
            <fpage>23</fpage>
            <page-range>23-29</page-range>
            <pub-id pub-id-type="pmid">31930227</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Poo</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Sriranganathan</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Segal</surname>
                <given-names>JP</given-names>
              </name>
            </person-group>
            <article-title>Network meta-analysis: efficacy of treatment for acute, chronic, and prevention of pouchitis in ulcerative colitis.</article-title>
            <source>Eur J Gastroenterol Hepatol</source>
            <year>2022</year>
            <month>May</month>
            <day>01</day>
            <volume>34</volume>
            <issue>5</issue>
            <fpage>518</fpage>
            <page-range>518-528</page-range>
            <pub-id pub-id-type="pmid">35271513</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goel</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Rahim</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Stave</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Nguyen</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Systematic review with meta-analysis: rifaximin for the prophylaxis of spontaneous bacterial peritonitis.</article-title>
            <source>Aliment Pharmacol Ther</source>
            <year>2017</year>
            <month>Dec</month>
            <volume>46</volume>
            <issue>11-12</issue>
            <fpage>1029</fpage>
            <page-range>1029-1036</page-range>
            <pub-id pub-id-type="pmid">28994123</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Waqas</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Mohib</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Saleem</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Lnu</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Arjumand</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Khalil</surname>
                <given-names>HHUR</given-names>
              </name>
              <name>
                <surname>Nosheen</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Maqsood</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Abbas</surname>
                <given-names>K</given-names>
              </name>
            </person-group>
            <article-title>Rifaximin Therapy for Patients With Metronidazole-Unresponsive Clostridium difficile Infection.</article-title>
            <source>Cureus</source>
            <year>2022</year>
            <month>Apr</month>
            <volume>14</volume>
            <issue>4</issue>
            <fpage>e24140</fpage>
            <pub-id pub-id-type="pmid">35582554</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Koo</surname>
                <given-names>HL</given-names>
              </name>
              <name>
                <surname>DuPont</surname>
                <given-names>HL</given-names>
              </name>
            </person-group>
            <article-title>Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases.</article-title>
            <source>Curr Opin Gastroenterol</source>
            <year>2010</year>
            <month>Jan</month>
            <volume>26</volume>
            <issue>1</issue>
            <fpage>17</fpage>
            <page-range>17-25</page-range>
            <pub-id pub-id-type="pmid">19881343</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Scarpignato</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Pelosini</surname>
                <given-names>I</given-names>
              </name>
            </person-group>
            <article-title>Rifaximin, a poorly absorbed antibiotic: pharmacology and clinical potential.</article-title>
            <source>Chemotherapy</source>
            <year>2005</year>
            <volume>51 Suppl 1</volume>
            <fpage>36</fpage>
            <page-range>36-66</page-range>
            <pub-id pub-id-type="pmid">15855748</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shayto</surname>
                <given-names>RH</given-names>
              </name>
              <name>
                <surname>Abou Mrad</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Sharara</surname>
                <given-names>AI</given-names>
              </name>
            </person-group>
            <article-title>Use of rifaximin in gastrointestinal and liver diseases.</article-title>
            <source>World J Gastroenterol</source>
            <year>2016</year>
            <month>Aug</month>
            <day>07</day>
            <volume>22</volume>
            <issue>29</issue>
            <fpage>6638</fpage>
            <page-range>6638-51</page-range>
            <pub-id pub-id-type="pmid">27547007</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r12">
          <label>12</label>
          <element-citation publication-type="book">
            <chapter-title>Rifaximin</chapter-title>
            <source>Drugs and Lactation Database (LactMed&#x000ae;) [Internet]</source>
            <publisher-name>National Institute of Child Health and Human Development</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>12</month>
            <day>3</day>
            <pub-id pub-id-type="pmid">30000968</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r13">
          <label>13</label>
          <element-citation publication-type="book">
            <chapter-title>Rifaximin</chapter-title>
            <source>LiverTox: Clinical and Research Information on Drug-Induced Liver Injury [Internet]</source>
            <publisher-name>National Institute of Diabetes and Digestive and Kidney Diseases</publisher-name>
            <publisher-loc>Bethesda (MD)</publisher-loc>
            <year>2018</year>
            <month>6</month>
            <day>14</day>
            <pub-id pub-id-type="pmid">31643412</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r14">
          <label>14</label>
          <element-citation publication-type="book">
            <person-group person-group-type="author">
              <name>
                <surname>Tsoris</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Marlar</surname>
                <given-names>CA</given-names>
              </name>
            </person-group>
            <chapter-title>Use Of The Child Pugh Score In Liver Disease</chapter-title>
            <source>StatPearls [Internet]</source>
            <publisher-name>StatPearls Publishing</publisher-name>
            <publisher-loc>Treasure Island (FL)</publisher-loc>
            <year>2023</year>
            <month>3</month>
            <day>13</day>
            <pub-id pub-id-type="pmid">31194448</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Rezaie</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Heimanson</surname>
                <given-names>Z</given-names>
              </name>
              <name>
                <surname>McCallum</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Pimentel</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Lactulose Breath Testing as a Predictor of Response to Rifaximin in Patients With Irritable Bowel Syndrome With Diarrhea.</article-title>
            <source>Am J Gastroenterol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>114</volume>
            <issue>12</issue>
            <fpage>1886</fpage>
            <page-range>1886-1893</page-range>
            <pub-id pub-id-type="pmid">31688023</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Majumder</surname>
                <given-names>MAA</given-names>
              </name>
              <name>
                <surname>Rahman</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Cohall</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Bharatha</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Singh</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Haque</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Gittens-St Hilaire</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>Antimicrobial Stewardship: Fighting Antimicrobial Resistance and Protecting Global Public Health.</article-title>
            <source>Infect Drug Resist</source>
            <year>2020</year>
            <volume>13</volume>
            <fpage>4713</fpage>
            <page-range>4713-4738</page-range>
            <pub-id pub-id-type="pmid">33402841</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28589.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Jones</surname>
                <given-names>LK</given-names>
              </name>
              <name>
                <surname>Ladd</surname>
                <given-names>IG</given-names>
              </name>
              <name>
                <surname>Gregor</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Evans</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Graham</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Gionfriddo</surname>
                <given-names>MR</given-names>
              </name>
            </person-group>
            <article-title>Understanding the medication prior-authorization process: A case study of patients and clinical staff from a large rural integrated health delivery system.</article-title>
            <source>Am J Health Syst Pharm</source>
            <year>2019</year>
            <month>Mar</month>
            <day>19</day>
            <volume>76</volume>
            <issue>7</issue>
            <fpage>453</fpage>
            <page-range>453-459</page-range>
            <pub-id pub-id-type="pmid">31361821</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
